Rhophylac Coupons & Savings Card – Discount Prices from $157.63

Rhophylac is a medication used to prevent Rh isoimmunization in Rh-negative individuals and to treat immune thrombocytopenic purpura (ITP) in certain patients. While it offers significant benefits, it's important to be aware of specific risks associated with its use.

Intravascular Hemolysis in ITP Treatment

In Rh-positive patients receiving Rhophylac for ITP, there have been reports of intravascular hemolysis—a condition where red blood cells are destroyed within the blood vessels. This can lead to severe anemia and, in rare cases, multi-organ failure, including acute respiratory distress syndrome (ARDS), acute kidney injury, and disseminated intravascular coagulation (DIC). Patients undergoing this treatment should be closely monitored in a healthcare setting for at least 8 hours post-administration. Signs to watch for include back pain, chills, fever, and discolored urine. If any of these symptoms occur, immediate medical attention is necessary.

Hypersensitivity Reactions

Although rare, severe allergic reactions to Rhophylac can occur. Symptoms may include hives, chest tightness, wheezing, low blood pressure, and anaphylaxis. If any of these signs appear, the administration of Rhophylac should be stopped immediately, and appropriate medical treatment should be provided.

Risk of Infectious Agents

Rhophylac is derived from human plasma, which carries a minimal risk of transmitting infectious agents, such as viruses or, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. While rigorous screening and manufacturing processes are in place to reduce this risk, it cannot be entirely eliminated. Patients should report any unusual symptoms to their healthcare provider promptly.

Considerations for Patients with Pre-existing Anemia

For patients with existing anemia, especially those being treated for ITP, Rhophylac may exacerbate the condition. The safety of Rhophylac in this group has not been fully established, so healthcare providers should carefully weigh the benefits against potential risks.

Interference with Laboratory Tests

Administration of Rhophylac can affect certain blood tests, including blood typing and antibody screening. This interference may also extend to tests performed on newborns whose mothers received Rhophylac during pregnancy. It's important to inform laboratory personnel about recent Rhophylac administration to ensure accurate test results.

Use in Specific Populations

• IgA Deficiency: Patients with IgA deficiency who have developed antibodies against IgA are at an increased risk of severe hypersensitivity reactions to Rhophylac. Its use is contraindicated in these individuals.

• Newborns: Rhophylac is intended for maternal administration and should not be given to newborn infants.

• Obese Patients: In individuals with a body mass index (BMI) of 30 or higher, intramuscular administration of Rhophylac may be less effective. In such cases, intravenous administration is recommended to ensure efficacy.

Being informed about these risks allows patients and healthcare providers to make educated decisions regarding the use of Rhophylac, ensuring safety and effectiveness in its application.

When considering the use of Rhophylac, it's important to be aware of potential interactions with other medications and vaccines:

Live Virus Vaccines: Rhophylac may interfere with the effectiveness of live vaccines such as measles, mumps, rubella, and varicella. To ensure optimal vaccine efficacy, it's recommended to postpone live vaccinations until at least three months after receiving Rhophylac. If Rhophylac is administered within two to four weeks of a live vaccine, the vaccine's effectiveness may be reduced.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Combining Rhophylac with NSAIDs like Diclofenac may increase the risk of kidney problems. Patients should be monitored for signs of kidney damage, including nausea, vomiting, changes in urination, sudden weight changes, swelling, shortness of breath, muscle cramps, fatigue, dizziness, confusion, or irregular heart rhythms.

Laboratory Tests: Rhophylac can affect the results of certain blood tests, such as blood typing, antibody screening, and the direct antiglobulin (Coombs') test. This interference may lead to misleading results, so it's important to inform healthcare providers about recent Rhophylac administration before undergoing these tests.

Always inform your healthcare provider about all medications, supplements, and vaccines you are taking or planning to receive to ensure safe and effective use of Rhophylac.